Brainstorm Cell Therapeutics 报告了季度亏损，低于分析师的预测，并获得了“持有”评级。 Brainstorm Cell Therapeutics reported a quarterly loss, missing analyst predictions, and received a "hold" rating.

Brainstorm Cell Therapeutics 报告称，季度亏损每股 0.51 美元，略低于分析师的预期。 Brainstorm Cell Therapeutics reported a quarterly loss of $0.51 per share, slightly missing analyst predictions. 生物技术公司开发神经退化性疾病的细胞疗法,开业时间为1.19美元。 The biotech company, which develops cellular therapies for neurodegenerative diseases, opened at $1.19 post-earnings. BCLI的市场上限为679万美元,P/E比率为-0.25,BCLI的比重为0.74。 With a market cap of $6.79 million, BCLI has a P/E ratio of -0.25 and a beta of 0.74. StockNews.com最近给予股票“控股”评分。 StockNews.com recently gave the stock a "hold" rating.